BioAtla (BCAB) Interest & Investment Income (2020 - 2026)
BioAtla (BCAB) posted quarterly Interest & Investment Income of $37000.0 for Q1 2026, down 90.75% year-over-year from $400000.0 in Q1 2025, and down 49.32% quarter-over-quarter from $73000.0 in Q4 2025.
BioAtla (BCAB) Interest & Investment Income (2020 - 2026) Analysis & Trends
BioAtla's Interest & Investment Income history runs 7 years deep, the most recent figure standing at $37000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 90.75% year-over-year to $37000.0; the TTM figure through Mar 2026 stood at $476000.0 (down 81.3% YoY), while the FY2025 annual figure was $843000.0, down 74.98% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $37000.0, down from $73000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1.7 million in Q3 2023, with the low at $37000.0 in Q1 2026.
- The 5-year median for Interest & Investment Income is $554000.0 (2024), against an average of $717941.2.
- The sharpest annual moves came in 2023 and 2026: Interest & Investment Income soared 1641.18% in 2023, then sank 90.75% in 2026.
- BioAtla's Interest & Investment Income stood at $1.0 million in 2022, then jumped by 56.45% to $1.6 million in 2023, then tumbled by 66.18% to $554000.0 in 2024, then tumbled by 86.82% to $73000.0 in 2025, then slumped by 49.32% to $37000.0 in 2026.
- Business Quant data shows BCAB's Interest & Investment Income at $37000.0 in Q1 2026, $73000.0 in Q4 2025, and $133000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 28.14 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 10.98 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 5.13 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 115.94 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | 16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16,000.00 |
| Mar 31, 2026 | 37,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | 133,000.00 |
| Jun 30, 2025 | 233,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 554,000.00 |
| Sep 30, 2024 | 692,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.73 Mn |
| Jun 30, 2023 | 1.46 Mn |
| Mar 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 1.05 Mn |
| Sep 30, 2022 | 370,000.00 |
| Jun 30, 2022 | 146,000.00 |
| Mar 31, 2022 | 85,000.00 |
| Dec 31, 2021 | 96,000.00 |
| Sep 30, 2021 | 76,000.00 |